RHYTHM PHARMACEUTICALS, INC. Interest Expense Nonoperating
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Interest Expense Nonoperating of $4.54 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $4.54M, a 21.95% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $4.58M, a 15.27% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $4.62M, a 15.27% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $4.74M, a 9.54% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $20.58M, a 0.10% decline from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $20.60M, a 48.31% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $13.89M, a 167.10% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $5.20M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.54M 10-Q · filed 2026-08-04 | $9.12M 10-Q · filed 2026-08-04 | $13.74M derived: sum of 3 quarters · filed 2026-08-04 | $18.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.58M 10-Q · filed 2026-05-05 | $9.20M derived: sum of 2 quarters · filed 2026-05-05 | $13.94M derived: sum of 3 quarters · filed 2026-05-05 | $19.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.36M derived: sum of 2 quarters · filed 2026-02-26 | $15.17M derived: sum of 3 quarters · filed 2026-08-04 | $20.58M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.74M 10-Q · filed 2025-11-04 | $10.56M derived: sum of 2 quarters · filed 2026-08-04 | $15.97M 10-Q · filed 2025-11-04 | $21.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.82M 10-Q · filed 2026-08-04 | $11.23M 10-Q · filed 2026-08-04 | $16.67M derived: sum of 3 quarters · filed 2026-08-04 | $21.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $5.41M 10-Q · filed 2026-05-05 | $10.86M derived: sum of 2 quarters · filed 2026-05-05 | $16.10M derived: sum of 3 quarters · filed 2026-05-05 | $20.70M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $5.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.69M derived: sum of 2 quarters · filed 2026-02-26 | $15.29M derived: sum of 3 quarters · filed 2026-02-26 | $20.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.24M 10-Q · filed 2025-11-04 | $9.85M derived: sum of 2 quarters · filed 2025-11-04 | $15.16M 10-Q · filed 2025-11-04 | $19.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.60M 10-Q · filed 2025-08-05 | $9.36M 10-Q · filed 2025-08-05 | $13.91M derived: sum of 3 quarters · filed 2026-02-26 | $17.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.75M 10-Q · filed 2025-05-07 | $9.30M derived: sum of 2 quarters · filed 2026-02-26 | $12.45M derived: sum of 3 quarters · filed 2026-02-26 | $15.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.70M derived: sum of 2 quarters · filed 2026-02-26 | $11.00M derived: sum of 3 quarters · filed 2026-02-26 | $13.89M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.15M 10-Q · filed 2024-11-06 | $6.45M derived: sum of 2 quarters · filed 2024-11-06 | $9.34M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $3.30M 10-Q · filed 2024-08-06 | $6.45M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $5.20M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |